BLUE bluebird bio Inc

Price (delayed)

$17.68

Market cap

$1.19B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$12.65

Enterprise value

$1.04B

bluebird bio, Inc., based in Cambridge, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders and cancer. The company's only - in the European Union - ...

Highlights
bluebird bio's debt has decreased by 3.5% from the previous quarter
The gross profit has plunged by 87% YoY and by 87% from the previous quarter
The revenue has dropped by 79% since the previous quarter and by 79% year-on-year

Key stats

What are the main financial stats of BLUE
Market
Shares outstanding
67.58M
Market cap
$1.19B
Enterprise value
$1.04B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.21
Price to sales (P/S)
23.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.7
Earnings
Revenue
$50.25M
EBIT
-$845.66M
EBITDA
-$824.38M
Free cash flow
-$675.66M
Per share
EPS
-$12.65
Free cash flow per share
-$10.01
Book value per share
$14.6
Revenue per share
$0.74
TBVPS
$21.12
Balance sheet
Total assets
$1.45B
Total liabilities
$469.9M
Debt
$198.6M
Equity
$984.56M
Working capital
$655.76M
Liquidity
Debt to equity
0.2
Current ratio
3.65
Quick ratio
3.46
Net debt/EBITDA
0.19
Margins
EBITDA margin
-1,640.7%
Gross margin
59.4%
Net margin
-1,676%
Operating margin
-1,725.5%
Efficiency
Return on assets
-49.4%
Return on equity
-66.5%
Return on invested capital
-64.8%
Return on capital employed
-70.1%
Return on sales
-1,683%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BLUE stock price

How has the bluebird bio stock price performed over time
Intraday
-0.67%
1 week
-2.86%
1 month
-3.18%
1 year
-67.65%
YTD
-59.14%
QTD
-44.72%

Financial performance

How have bluebird bio's revenue and profit performed over time
Revenue
$50.25M
Gross profit
$29.85M
Operating income
-$867.01M
Net income
-$842.13M
Gross margin
59.4%
Net margin
-1,676%
The gross profit has plunged by 87% YoY and by 87% from the previous quarter
The revenue has dropped by 79% since the previous quarter and by 79% year-on-year
The gross margin has contracted by 39% YoY and by 39% from the previous quarter
The company's net income fell by 35% QoQ and by 29% YoY

Growth

What is bluebird bio's growth rate over time

Valuation

What is bluebird bio stock price valuation
P/E
N/A
P/B
1.21
P/S
23.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.7
The EPS has declined by 34% since the previous quarter and by 7% year-on-year
BLUE's P/B is 66% below its 5-year quarterly average of 3.6 and 42% below its last 4 quarters average of 2.1
bluebird bio's equity has decreased by 41% YoY and by 18% from the previous quarter
BLUE's P/S is 84% below its 5-year quarterly average of 151.1 but 24% above its last 4 quarters average of 19.1
The revenue has dropped by 79% since the previous quarter and by 79% year-on-year

Efficiency

How efficient is bluebird bio business performance
bluebird bio's ROE has plunged by 54% from the previous quarter and by 41% YoY
bluebird bio's ROA has decreased by 48% from the previous quarter and by 37% YoY
bluebird bio's return on invested capital has decreased by 31% QoQ and by 19% YoY

Dividends

What is BLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BLUE.

Financial health

How did bluebird bio financials performed over time
The quick ratio has plunged by 57% YoY and by 31% from the previous quarter
The current ratio has plunged by 55% YoY and by 31% from the previous quarter
bluebird bio's debt is 80% less than its equity
BLUE's debt to equity has surged by 67% year-on-year and by 18% since the previous quarter
bluebird bio's equity has decreased by 41% YoY and by 18% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.